UK Antibiotic Resistance: 406 Resistant Bloodstream Infections a Week—But the Data Need Context
UKHSA reports an average of 406 resistant bacteraemia episodes per week in 2025, up 16.8% from 2019. The agency notes that some broader bloodstream-infection increases are driven by reporting factors and need investigation.
The UK Health Security Agency says an average of 406 antibiotic-resistant bloodstream infection episodes were reported each week in 2025. Its annual surveillance report counted 21,129 episodes resistant to one or more critically important antibiotics, up 16.8% from 18,086 in 2019.
The headline figure is serious, but it needs to be read precisely. UKHSA distinguishes the estimated burden of resistant bacteraemia from the total number of bloodstream infection episodes. The latter rose 22.9% over the same period, and the agency says nearly half of that increase was driven by coagulase-negative staphylococci, bacteria that can be contaminants in blood cultures. The report says the clinical significance and drivers of that rise require further investigation.
That nuance does not erase the resistance trend. A resistant bloodstream infection can be difficult to treat and potentially life-threatening. But headlines that conflate every reported bacteraemia episode with a confirmed resistant infection risk overstating what the data show.
There are also signs of mixed progress. UKHSA says antibiotic use in the NHS fell by 10.7% between 2019 and 2025, and the rate of increase in resistant infections slowed from 9.3% in 2024 to 3.2% in 2025. These numbers suggest the problem is worsening more slowly, not that it has been solved.
Antimicrobial resistance is shaped by prescribing practices, infection prevention, hospital capacity, antibiotic development and access to timely diagnosis. Reducing unnecessary use is important, but patients still need antibiotics when bacterial infections warrant them. The challenge is avoiding both overuse and delays in treatment.
The report raises a practical question for policymakers: where should resources go first—better infection control, faster diagnostics, surveillance or new medicines? And how can public communication convey a growing risk without blurring the difference between resistant cases and broader reporting trends?